Analyte Gravimetrically Weighted Value Units Reconstituted
Stability (Days)
α-Hydroxyalprazolam 225 ng/mL 25 days
Amobarbital 225 ng/mL 25 days
d-Amphetamine 375 ng/mL 25 days
(±)-3,4-Methylenedioxyamphetamine (MDA) 375 ng/mL 25 days
d-Methamphetamine 375 ng/mL 25 days
(±)-3,4-Methylenedioxymethamphetamine (MDMA) 375 ng/mL 25 days
(±)-3,4-Methylenedioxyethylamphetamine (MDEA) 375 ng/mL 25 days
Benzoylecgonine (BE) 112.5 ng/mL 25 days
Butalbital 225 ng/mL 25 days
Codeine 1,500 ng/mL 25 days
Nordiazepam 225 ng/mL 25 days
Hydrocodone 300 ng/mL 25 days
Hydromorphone 300 ng/mL 25 days
Lorazepam 225 ng/mL 25 days
Methadone 225 ng/mL 25 days
Methadone Primary Metabolite (EDDP) 225 ng/mL 25 days
Methaqualone 225 ng/mL 25 days
Morphine-3-β-D-Glucuronide 2,430
(Equivalent to 1,500 free Morphine)
ng/mL 25 days
6-Monoacetylmorphine (6-MAM) 7.5 ng/mL 25 days
Nortriptyline 225 ng/mL 25 days
Oxazepam 225 ng/mL 25 days
Oxycodone 225 ng/mL 25 days
Oxymorphone 225 ng/mL 25 days
Pentobarbital 225 ng/mL 25 days
Phencyclidine (PCP) 18.75 ng/mL 25 days
Phenobarbital 225 ng/mL 25 days
Norpropoxyphene 225 ng/mL 25 days
Secobarbital 225 ng/mL 25 days
Temazepam 225 ng/mL 25 days
(l)-9-Carboxy-11-nor-Delta-9-THC (THC-COOH) 11.25 ng/mL 25 days

Product Contains: α‑Hydroxyalprazolam, Amobarbital, d‑Amphetamine, (±)‑3,4‑Methylenedioxyamphetamine (MDA), d‑Methamphetamine, (±)‑3,4‑Methylenedioxymethamphetamine (MDMA), (±)‑3,4‑Methylenedioxyethylamphetamine (MDEA), Benzoylecgonine (BE), Butalbital, Codeine, Nordiazepam, Hydrocodone, Hydromorphone, Lorazepam, Methadone, Methadone Primary Metabolite (EDDP), Methaqualone, Morphine‑3‑β‑D‑Glucuronide, 6‑Monoacetylmorphine (6‑MAM), Nortriptyline, Oxazepam, Oxycodone, Oxymorphone, Pentobarbital, Phencyclidine (PCP), Phenobarbital, Norpropoxyphene, Secobarbital, Temazepam, (l)‑9‑Carboxy‑11‑nor‑Delta‑9‑THC (THC‑COOH)

Matrix Urine
Unit Size 4x10mL
Form Lyophilized
Shelf Life 30 months
Stability 25 days
Storage Store dried control material at 2-8ºC (35-46ºF).

Description

For the purposes of drugs of abuse screening it is necessary to have a set of controls with high, intermediate and low drug concentrations. These cutoff controls allow identification of various levels of abuse.

Downloads

Urine SDS | Download PDF
IFU for Lot #A9743 | Download PDF
IFU for Lot #A7194 | Download PDF

Sign Up for Weekly Updates

  • This field is for validation purposes and should be left unchanged.